Cardiac developmental biology lessons with focus on new insights in transcriptional and epigenetic pathways controlling differentiation and maturation. What can be learned from ES cells and embryology about cardiac cell fate? How to direct the fate of iPS, and pluripotent spermatogonial stem cells toward cardiac progenitors?
Cardiogenesis: an embryological perspective: lessons from cardiogenic transcriptional pathway analysis Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors . Human induced pluripotent stem cells as a source for multipotent cardiovascular progenitors. Functional properties of germ cell or hair follicle-derived cardiac myocytes Functional properties of parthenogenetic stem cell derived cardiac myocytes Bmp signaling exerts opposing effects on cardiogenic differentiation in the embryo
Optimisation of human cardiac differentiation under defined conditions and selection of cell types Guided cardiopoiesis of mesenchymal stem cells as a paradigm for cardiac maturation Wnt/beta-catenin and SCa-1. Isolation, expansion and functional characterization of human c-kit cardiac progenitor cells
Do cell-related factors impact on functional repair capacity? Choice and differentiation state of cells, selected, clonogenic cell lines versus unselected heterogeneous outgrowth populations, impact of senescence on repair capacity?
MicroRNAs controlling cardiac cell fate: impact on therapeutic potency Senescence of CSCs: functional implications? Cardiospheres and cardiosphere-derived cells for myocardial repair: are mixed outgrowth cells superior to selected CSCs?
Role of NO in cardiac progenitor cell maturation Cardiac stem cells and tissue engineering Implication of the cardiac progenitor cell niche for survival and differentiation of endogenous and transplanted progenitor cells. Vascular progenitors: the missing link for true cardiac repair. The multifaceted progenitors with distinct phenotypes and paracrine release? Mediators of effect: do the cells or factors released by CSCs bring the benefit – if any?
Targeting HF patients that may benefit from cell transfer and how to assess in vivo effects of stem cells. Patient- and cell-related factors: How to assess the ability to mediate functional or structural repair? Autologous versus allogenic approach, cell dose and mode of administration, immunological aspects, design of trail: choice of endpoints, power, ethics…
Molecular imaging approaches to assess stem cell effects in vivo: best guide to determine cell dose, type, and mode of administration Metabolic imaging of stem cell effects in patients: how do we evaluate it and impact on future trials? Prespecified mesenchymal stem cells in patients with chronic ischemic dysfunction: how do we evaluate clinical effects in vivo? Multimodal functional and structural imaging to evaluate in vivo effects of progenitor cells: tools for cell trial design in heart failure Putting results of stem cell trials in the dysfunctional heart in perspective with recent drug trials: the heart failure trialists’ view. The unmet need in heart failure treatment: how to target patients in need of cell therapy?
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved